0/541991 JC12 Rec'd PCT/FT

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** Not Yet Assigned Filing Date Herewith - July 5, 2005 INFORMATION DISCLOSURE First Named Inventor Mohammad R. Marzabadi STATEMENT BY APPLICANT Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned (Use as many sheets as necessary) Attorney Docket Number 65369-US-PCT1

3

Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (d known)}			Figures Appear
		^{US-} 6,727,264	04/27/2004	Marzabadi, et al.	
		^{US-} 6,441,000	08/27/2002	Gibson, et al.	
		^{US-} 5,459,151	10/17/1995	Lombardo	
		^{US-} 2004/0186103	09/23/2004	Marzabadi, et al.	
		^{US-} 2004/0073036	04/15/2004	Marzabadi, et al.	
		^{US-} 2004/0038855	02/26/2004	Salon, et al.	
		^{US-} 2003/0077701	04/24/2003	Salon, et al.	
		^{US-} 10/719,358	Not Yet Published	Marzabadi, et al.	
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	,
		US-			•
		US-		THE PERSON OF TH	
		US			
		US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	١.	
Initials*	No.'	Country Code ³ Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T*	
		′ WO 04/058727	07/15/2004	Bayer Pharmaceuticals	-		
		, WO 04/005257	01/15/2004	Synaptic Pharmaceutical			
***************************************		, WO 04/004714	01/15/2004	Synaptic Pharmaceutical			
***************************************		. WO 03/004027	01/16/2003	Synaptic Pharmaceutical	***************************************		
	1	· WO 02/094799	11/28/2002	Neurogen	•••••••••••••••••••••••••••••••••••••••		

					_
			 		_
- 1	Examiner		Date		1
	Signature	•		1	ı
	Signature		Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant, 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/541991 JC12 Rec'd PCT/PTC 0 5 JUL 2005

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

 Under the Paperwork Reduction Act of 1995, no persons are requisited. Substitute for form 1449A/PTO 	Con	nplete if Known
	Application Number	Not Yet Assigned
INFORMATION DISCLOSURE	Filing Date	Herewith - July 5, 2005
STATEMENT BY APPLICANT	First Named Inventor	Mohammad R. Marzabadi
OTATEMENT BY ALL COANT	Art Unit	Not Yet Assigned
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned
Sheet 2 of 3	Attorney Docket Number	65369-US-PCT1

Examiner	Cite	Document Number	U. S. PATENT D Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			,
		US-			
		US-			
	<u> </u>	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-		- U-L	
	l	US-			
		US-			
		US⊦		· · · · · · · · · · · · · · · · · · ·	
		US-			4
		US-			
		US-		*	
		US-	•		
		US-			-
		US-		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°	
		, WO 02/030927	04/18/2002	Pierre Fabre Medicament			
		₹ WO 02/006245	01/24/2002	Synaptic Pharmaceutical			
***************************************	1	₹ WO 02/002744	01/10/2002	Synaptic Pharmaceutical			
***************************************	ļ	/ WO 00/021934	04/20/2000	Astra Zeneca	***************************************		

Examiner	· · · · · · · · · · · · · · · · · · ·	Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/541991 JC12 Rec'd PCT/PTC 05 JUL 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		ot of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Substitute for form 1449/PTO			Application Number	Not Yet Assigned		
INFORMAT	TION DIS	CLOSURE	Filing Date	Herewith - July 5, 2005		
STATEME	STATEMENT BY APPLICANT			Mohammad R. Marzabadi		
// too no m	any chaota as n		Art Unit	Not Yet Assigned		
(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned		
Sheet 3	of	3	Attorney Docket Number	65369-US-PCT1		

Examiner Initials* No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issunumber(s), publisher, city and/or country where published.						
		TAKEKAWA, S., et al., "T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist", European Journal of Pharmacology, March 2002, 438, pp. 129-135				
7 1 27 7						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.